Please login to the form below

Not currently logged in
Email:
Password:

Samsung BioLogics

This page shows the latest Samsung BioLogics news and features for those working in and with pharma, biotech and healthcare.

GSK and Vir Biotech expand phase 3 COVID-19 antibody study

GSK and Vir Biotech expand phase 3 COVID-19 antibody study

The Biogen agreement builds on Vir Biotech’s additional manufacturing agreements with China-based WuXi Biologics and Incheon, South Korea-headquartered Samsung Biologics.

Latest news

  • Biogen launches Remicade biosimilar in the UK Biogen launches Remicade biosimilar in the UK

    Developed by Samsung Bioepis - a joint venture between Biogen and Samsung BioLogics - and marketed in the EU by Biogen, Flixabi (infliximab) won EU marketing authorisation in May this year.

  • Second Remicade biosimilar given green light in Europe Second Remicade biosimilar given green light in Europe

    Samsung Bioepis’ Flixabi provides another lower-cost treatment option. Samsung Bioepis has been given EU approval for Flixabi, their biosimilar version of Johnson &Johnson's immunology blockbuster Remicade. ... year. It has been developed by Samsung

  • UCB to sell Biogen Idec’s MS drugs in Asia UCB to sell Biogen Idec’s MS drugs in Asia

    US-based Biogen Idec's previosu experience in the Asian market includes a biosimialrs joint venture with Korea's Samsung Biologics known as Samsung Bioepis.

  • Biogen Idec licenses anti-TNF biosimilars Biogen Idec licenses anti-TNF biosimilars

    Treatment prospects emerge from joint venture with Samsung Biologics.  . Biogen Idec says it has licensed multiple biosimilars of anti-tumour necrosis factor (TNF) developed at its joint venture with Korea's ... Samsung Biologics.

  • Roche signs biologics partnership with Samsung Roche signs biologics partnership with Samsung

    Swiss pharma company Roche has signed a biologics manufacturing deal with Samsung BioLogics. ... Tae-Han Kim, president and CEO of Samsung BioLogics, said: "We are pleased to announce this strategic manufacturing relationship with Roche and look forward

More from news
Approximately 2 fully matching, plus 6 partially matching documents found.

Latest Intelligence

  • Pharma deals during July 2012 Pharma deals during July 2012

    Two weeks prior to the announcement of the collaboration between Amgen and Watson, Biogen Idec and Samsung Biologics announced the establishment of a $300m joint venture to develop and commercialise biosimilars.

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

PMEA Awards 2020

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
EPG Health

REACH, ENGAGE & MEASURE - Accomplish meaningful HCP engagement via Medthority, our trusted independent medical website. Support education and treatment...

Latest intelligence

#DemandDiversity: For International Women's Day, we ask... why do women often suffer from more side effects than men?
Women are largely prescribed exactly the same treatment regimens as men, with no account for the underlying differences in physiology and drug metabolism between the sexes....
Good design saves lives
Good design and creative thinking are essential if we are to improve on existing problems in new ways, which is why design and creativity within healthcare is vital. Health is...
Why you must understand the pricing of patient recruitment companies
Recruiting a diverse range of patients and engaging with them for your clinical trial isn’t an easy task, which means you might turn to patient recruitment companies, like us, who...

Infographics